![James F. Howard, Jr., MD](https://news.unchealthcare.org/wp-content/uploads/sites/1159/2020/08/efgartigimod-found-to-improve-symptoms-of-patients-with-generalized-myasthenia-gravis-image2-scaled-1-600x750.jpeg)
January 3, 2022
FDA Approves New Drug to Treat Generalized Myasthenia Gravis
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.